Thrombin-mediated hepatocellular carcinoma cell migration: Cooperative action via proteinase-activated receptors 1 and 4

Proteinase‐activated receptor‐1 (PAR1), a thrombin receptor and the prototype of a newly discovered G‐protein‐coupled receptor subfamily, plays an important role in tumor development and progression. In this study, we documented the expression of the thrombin receptors PAR1, PAR3, and PAR4 in perman...

Full description

Saved in:
Bibliographic Details
Published inJournal of cellular physiology Vol. 211; no. 3; pp. 699 - 707
Main Authors Kaufmann, Roland, Rahn, Stephanie, Pollrich, Kristin, Hertel, Julia, Dittmar, Yves, Hommann, Merten, Henklein, Peter, Biskup, Christoph, Westermann, Martin, Hollenberg, Morley D., Settmacher, Utz
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.06.2007
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Proteinase‐activated receptor‐1 (PAR1), a thrombin receptor and the prototype of a newly discovered G‐protein‐coupled receptor subfamily, plays an important role in tumor development and progression. In this study, we documented the expression of the thrombin receptors PAR1, PAR3, and PAR4 in permanent hepatocellular carcinoma (HCC) cell lines and primary HCC cell cultures. Stimulation of HCC cells with thrombin and the PAR1‐selective activating peptide, TFLLRN‐NH2, increased transmembrane migration across a collagen barrier. This effect was blocked by the PAR1 antagonist SCH 79797, confirming that the PAR1 thrombin receptor subtype is involved in regulating hepatoma cell migration. In addition, the PAR4‐selective agonist, AYPGKF‐NH2, also stimulated HCC cell migration whilst the PAR4 antagonist, trans‐cinnamoyl‐YPGKF‐NH2, attenuated the effect of thrombin on HCC cell migration. PAR1‐ and PAR4‐triggered HCC cell migration was blocked by inhibiting a number of key mediators of signal transduction, including G proteins of the Gi/Go family, matrix metalloproteinases, ERK/MAPKinase, cyclic AMP‐dependent protein kinase, Src tyrosine kinase, and the EGF receptor kinase. Our data point to a cooperative PAR1/PAR4 signaling network that contributes to thrombin‐mediated tumor cell migration. We suggest that a combined inhibition of coagulation cascade serine proteinases, the two PARs and their complex signaling pathways may provide a new strategy for treating hepatocellular carcinoma. J. Cell. Physiol. 211: 699–707, 2007. © 2007 Wiley‐Liss, Inc.
AbstractList Abstract Proteinase‐activated receptor‐1 (PAR 1 ), a thrombin receptor and the prototype of a newly discovered G‐protein‐coupled receptor subfamily, plays an important role in tumor development and progression. In this study, we documented the expression of the thrombin receptors PAR 1 , PAR 3 , and PAR 4 in permanent hepatocellular carcinoma (HCC) cell lines and primary HCC cell cultures. Stimulation of HCC cells with thrombin and the PAR 1 ‐selective activating peptide, TFLLRN‐NH 2 , increased transmembrane migration across a collagen barrier. This effect was blocked by the PAR 1 antagonist SCH 79797, confirming that the PAR 1 thrombin receptor subtype is involved in regulating hepatoma cell migration. In addition, the PAR 4 ‐selective agonist, AYPGKF‐NH 2 , also stimulated HCC cell migration whilst the PAR 4 antagonist, trans‐cinnamoyl‐YPGKF‐NH 2 , attenuated the effect of thrombin on HCC cell migration. PAR 1 ‐ and PAR 4 ‐triggered HCC cell migration was blocked by inhibiting a number of key mediators of signal transduction, including G proteins of the G i /G o family, matrix metalloproteinases, ERK/MAPKinase, cyclic AMP‐dependent protein kinase, Src tyrosine kinase, and the EGF receptor kinase. Our data point to a cooperative PAR 1 /PAR 4 signaling network that contributes to thrombin‐mediated tumor cell migration. We suggest that a combined inhibition of coagulation cascade serine proteinases, the two PARs and their complex signaling pathways may provide a new strategy for treating hepatocellular carcinoma. J. Cell. Physiol. 211: 699–707, 2007. © 2007 Wiley‐Liss, Inc.
Proteinase-activated receptor-1 (PAR(1)), a thrombin receptor and the prototype of a newly discovered G-protein-coupled receptor subfamily, plays an important role in tumor development and progression. In this study, we documented the expression of the thrombin receptors PAR(1), PAR(3), and PAR(4) in permanent hepatocellular carcinoma (HCC) cell lines and primary HCC cell cultures. Stimulation of HCC cells with thrombin and the PAR(1)-selective activating peptide, TFLLRN-NH(2), increased transmembrane migration across a collagen barrier. This effect was blocked by the PAR(1) antagonist SCH 79797, confirming that the PAR(1) thrombin receptor subtype is involved in regulating hepatoma cell migration. In addition, the PAR(4)-selective agonist, AYPGKF-NH(2), also stimulated HCC cell migration whilst the PAR(4) antagonist, trans-cinnamoyl-YPGKF-NH(2), attenuated the effect of thrombin on HCC cell migration. PAR(1)- and PAR(4)-triggered HCC cell migration was blocked by inhibiting a number of key mediators of signal transduction, including G proteins of the G(i)/G(o) family, matrix metalloproteinases, ERK/MAPKinase, cyclic AMP-dependent protein kinase, Src tyrosine kinase, and the EGF receptor kinase. Our data point to a cooperative PAR(1)/PAR(4) signaling network that contributes to thrombin-mediated tumor cell migration. We suggest that a combined inhibition of coagulation cascade serine proteinases, the two PARs and their complex signaling pathways may provide a new strategy for treating hepatocellular carcinoma.
Proteinase‐activated receptor‐1 (PAR1), a thrombin receptor and the prototype of a newly discovered G‐protein‐coupled receptor subfamily, plays an important role in tumor development and progression. In this study, we documented the expression of the thrombin receptors PAR1, PAR3, and PAR4 in permanent hepatocellular carcinoma (HCC) cell lines and primary HCC cell cultures. Stimulation of HCC cells with thrombin and the PAR1‐selective activating peptide, TFLLRN‐NH2, increased transmembrane migration across a collagen barrier. This effect was blocked by the PAR1 antagonist SCH 79797, confirming that the PAR1 thrombin receptor subtype is involved in regulating hepatoma cell migration. In addition, the PAR4‐selective agonist, AYPGKF‐NH2, also stimulated HCC cell migration whilst the PAR4 antagonist, trans‐cinnamoyl‐YPGKF‐NH2, attenuated the effect of thrombin on HCC cell migration. PAR1‐ and PAR4‐triggered HCC cell migration was blocked by inhibiting a number of key mediators of signal transduction, including G proteins of the Gi/Go family, matrix metalloproteinases, ERK/MAPKinase, cyclic AMP‐dependent protein kinase, Src tyrosine kinase, and the EGF receptor kinase. Our data point to a cooperative PAR1/PAR4 signaling network that contributes to thrombin‐mediated tumor cell migration. We suggest that a combined inhibition of coagulation cascade serine proteinases, the two PARs and their complex signaling pathways may provide a new strategy for treating hepatocellular carcinoma. J. Cell. Physiol. 211: 699–707, 2007. © 2007 Wiley‐Liss, Inc.
Author Hollenberg, Morley D.
Hommann, Merten
Biskup, Christoph
Dittmar, Yves
Hertel, Julia
Pollrich, Kristin
Rahn, Stephanie
Westermann, Martin
Kaufmann, Roland
Henklein, Peter
Settmacher, Utz
Author_xml – sequence: 1
  givenname: Roland
  surname: Kaufmann
  fullname: Kaufmann, Roland
  email: roland.kaufmann@med.uni-jena.de
  organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany
– sequence: 2
  givenname: Stephanie
  surname: Rahn
  fullname: Rahn, Stephanie
  organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany
– sequence: 3
  givenname: Kristin
  surname: Pollrich
  fullname: Pollrich, Kristin
  organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany
– sequence: 4
  givenname: Julia
  surname: Hertel
  fullname: Hertel, Julia
  organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany
– sequence: 5
  givenname: Yves
  surname: Dittmar
  fullname: Dittmar, Yves
  organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany
– sequence: 6
  givenname: Merten
  surname: Hommann
  fullname: Hommann, Merten
  organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany
– sequence: 7
  givenname: Peter
  surname: Henklein
  fullname: Henklein, Peter
  organization: Institute of Biochemistry, Charité, Humboldt University of Berlin, Berlin, Germany
– sequence: 8
  givenname: Christoph
  surname: Biskup
  fullname: Biskup, Christoph
  organization: Institute of Physiology II, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany
– sequence: 9
  givenname: Martin
  surname: Westermann
  fullname: Westermann, Martin
  organization: Electron Microscopy Center, Medical Faculty at the Friedrich Schiller University Jena, Germany
– sequence: 10
  givenname: Morley D.
  surname: Hollenberg
  fullname: Hollenberg, Morley D.
  organization: Canadian Institutes of Health Research Proteinases and Inflammation Network, Endocrine-Diabetes, Smooth Muscle and Mucosal Inflammation Groups, Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Canada
– sequence: 11
  givenname: Utz
  surname: Settmacher
  fullname: Settmacher, Utz
  organization: Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, Jena, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/17323377$$D View this record in MEDLINE/PubMed
BookMark eNp1kM1u1DAURi3Uik4LC14AeYXEIq1_4njMDo1gAFUtEkUgNtaNfUNdkji1M0P79iSdga5YWf587tH1d0wO-tgjIS84O-WMibMbN5wKzoR-QhacGV2UlRIHZDG98cKokh-R45xvGGPGSPmUHHEthZRaL8jd1XWKXR36okMfYERPr3GAMTps200LiTpILvSxAzpHtAs_E4wh9m_oKsYB58sWKbg5o9sAdEhxxNBDxmJOtw_ShA6HMaZMOYXe0_IZOWygzfh8f56Qr-_fXa0-FOeX64-rt-eFK4XWhWfg0INUxjFeSe3ZktdgGsG9a5hTsMSmdLVWpnKmlkYYD6pkbqml9Bq8PCGvdt5prdsN5tF2Ic8_gR7jJlvNpORyKSbw9Q50KeacsLFDCh2ke8uZnWu2U832oeaJfbmXbuqpt0dy3-sEnO2A36HF-_-b7KfV57_KYjcR8oh3_yYg_bKVllrZbxdru66-fFc_SmWl_AMcvZoB
CitedBy_id crossref_primary_10_3390_cancers14143412
crossref_primary_10_2217_epi_2017_0101
crossref_primary_10_1245_s10434_010_1163_4
crossref_primary_10_1289_ehp_1306937
crossref_primary_10_1007_s00018_011_0678_6
crossref_primary_10_1093_abbs_gmu108
crossref_primary_10_1002_ijc_24070
crossref_primary_10_1007_s10735_010_9274_6
crossref_primary_10_1245_s10434_012_2338_y
crossref_primary_10_3892_ol_2011_291
crossref_primary_10_7314_APJCP_2013_14_6_3793
crossref_primary_10_1186_1478_811X_11_86
crossref_primary_10_1007_s00432_010_0961_1
crossref_primary_10_1021_acsmedchemlett_8b00538
crossref_primary_10_1002_jcb_22608
crossref_primary_10_1016_j_biocel_2011_05_008
crossref_primary_10_1155_2015_840542
crossref_primary_10_1186_s12964_020_00552_7
crossref_primary_10_1002_ijc_29537
crossref_primary_10_1155_2015_437695
crossref_primary_10_33160_yam_2021_05_007
crossref_primary_10_1126_scisignal_2003813
crossref_primary_10_1096_fj_14_252551
crossref_primary_10_1111_j_1538_7836_2011_04447_x
crossref_primary_10_1007_s00432_014_1863_4
crossref_primary_10_3892_ol_2018_9407
crossref_primary_10_1038_onc_2008_488
crossref_primary_10_1093_ije_dyu006
crossref_primary_10_1371_journal_pone_0122678
crossref_primary_10_1016_j_brainresrev_2007_08_002
crossref_primary_10_1517_13543776_2010_487864
crossref_primary_10_3748_wjg_v20_i34_11977
crossref_primary_10_1155_2018_4735752
crossref_primary_10_1002_JLB_3MR0120_390R
crossref_primary_10_1111_j_1478_3231_2012_02865_x
crossref_primary_10_1371_journal_pone_0094993
crossref_primary_10_1093_gigascience_giad117
crossref_primary_10_1016_j_pharmthera_2011_01_003
crossref_primary_10_1093_carcin_bgp153
Cites_doi 10.1182/blood.V95.10.3133
10.1161/CIRCULATIONAHA.105.587758
10.1016/0092-8674(91)90261-V
10.1152/physrev.00028.2003
10.1038/47260
10.1038/nm0898-909
10.1002/(SICI)1097-0142(19971201)80:11<2068::AID-CNCR5>3.0.CO;2-T
10.1074/jbc.M513138200
10.1586/14779072.2.5.777
10.1016/0003-2697(76)90527-3
10.1038/35007085
10.1096/fj.02-0316com
10.1074/jbc.M312090200
10.1139/y01-013
10.1038/386502a0
10.1055/s-2003-40962
10.1016/0014-5793(91)81017-3
10.1124/pr.54.2.203
10.1074/jbc.M213091200
10.1073/pnas.0406682102
10.1182/blood.V92.10.3694
10.1126/science.6836310
10.1016/j.cell.2004.12.018
10.1210/er.2003-0025
10.1016/S0090-4295(02)01969-6
10.3322/canjclin.55.2.74
10.1097/00043426-200005000-00019
10.1016/S0002-9440(10)64675-5
10.1073/pnas.95.12.6642
10.1055/s-2005-871200
10.1002/hep.21196
10.1074/jbc.M007027200
10.1073/pnas.91.20.9208
10.1016/S0021-9258(18)43613-7
10.1158/1541-7786.395.2.7
10.1007/BF00132981
10.1097/00062752-199603050-00008
10.1055/s-0037-1616053
10.1038/sj.onc.1206453
10.1016/S0002-9440(10)64283-6
10.1038/sj.bjc.6690063
10.1182/blood-2004-03-1047
10.1016/S0006-2952(00)00460-3
ContentType Journal Article
Copyright Copyright © 2007 Wiley‐Liss, Inc.‐Wiley‐Liss, Inc.
Copyright_xml – notice: Copyright © 2007 Wiley‐Liss, Inc.‐Wiley‐Liss, Inc.
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1002/jcp.21027
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Biology
EISSN 1097-4652
EndPage 707
ExternalDocumentID 10_1002_jcp_21027
17323377
JCP21027
ark_67375_WNG_G6SX5Z45_3
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Canadian Institutes of Health Research
– fundername: Servier International Alliance Project
– fundername: Proteinases and Inflammation (PAIN) Group
– fundername: Interdisciplinary Center for Clinical Research (ICCR) Jena
  funderid: B 307‐04004
GroupedDBID ---
-DZ
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
36B
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
85S
8UM
930
9M8
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDPE
ABEFU
ABEML
ABIJN
ABJNI
ABPPZ
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACNCT
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AIAGR
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BQCPF
BROTX
BRXPI
BSCLL
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMB
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
H~9
IH2
IX1
J0M
JPC
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M56
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MVM
MXFUL
MXSTM
N04
N05
N9A
NEJ
NF~
NNB
O66
O9-
OHT
OIG
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
ROL
RWI
RWR
RX1
RYL
S10
SAMSI
SUPJJ
SV3
TN5
TWZ
UB1
UPT
V2E
V8K
VQP
W8V
W99
WBKPD
WH7
WIB
WIH
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WXSBR
WYB
WYISQ
X7M
XG1
XJT
XOL
XPP
XSW
XV2
Y6R
YQT
YZZ
ZGI
ZXP
ZZTAW
~IA
~WT
AETEA
G8K
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c4277-d0aceda359c01637d081ba9f21dcf0c5a8ef4cb7596c9b3929da540c8733d7ad3
IEDL.DBID DR2
ISSN 0021-9541
IngestDate Sat Aug 17 04:17:07 EDT 2024
Thu Sep 26 17:27:38 EDT 2024
Sat Sep 28 07:56:34 EDT 2024
Sat Aug 24 01:01:07 EDT 2024
Wed Oct 30 09:50:44 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4277-d0aceda359c01637d081ba9f21dcf0c5a8ef4cb7596c9b3929da540c8733d7ad3
Notes Proteinases and Inflammation (PAIN) Group
ark:/67375/WNG-G6SX5Z45-3
Servier International Alliance Project
Interdisciplinary Center for Clinical Research (ICCR) Jena - No. B 307-04004
Canadian Institutes of Health Research
istex:608CBE0A0B702DDF8E5599C369DDC6BBA75DE41A
ArticleID:JCP21027
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 17323377
PQID 70331382
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_70331382
crossref_primary_10_1002_jcp_21027
pubmed_primary_17323377
wiley_primary_10_1002_jcp_21027_JCP21027
istex_primary_ark_67375_WNG_G6SX5Z45_3
PublicationCentury 2000
PublicationDate June 2007
PublicationDateYYYYMMDD 2007-06-01
PublicationDate_xml – month: 06
  year: 2007
  text: June 2007
PublicationDecade 2000
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: United States
PublicationTitle Journal of cellular physiology
PublicationTitleAlternate J. Cell. Physiol
PublicationYear 2007
Publisher Wiley Subscription Services, Inc., A Wiley Company
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
References Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. 1994. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 91: 9208-9212.
Kamath L, Meydani A, Foss F, Kuliopulos A. 2001. Signaling form protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res 61: 5933-5940.
Ruf W, Mueller BM. 1996. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 3: 379-384.
Fischer EG, Ruf W, Mueller BM. 1995. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 55: 1629-1632.
Zacharski LR, Hommann M, Kaufmann R. 2004. Rationale for clinical trials of coagulation: Reactive drugs in hepatocellular carcinoma. Expert Rev Cardiovasc Ther 2: 777-784.
Palumbo JS, Degen JD. 2000. Hemostatic factors in tumor biology. J Pediatr Hematol Oncol 22: 281-287.
Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, Diamandis EP, Hollenberg MD. 2006. Proteinase-activated receptors, targets for Kallikrein signaling. J Biol Chem 281: 32095-32112.
Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. 2002. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 104: 2746-2751.
Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, Hollenberg MD. 2005. Proteinase-activated receptors: Transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26: 1-43.
Lynn M, Nierodzik ML, Kajumo LR, Karpatkin S. 1992. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 52: 3267-3272.
Sabri A, Guo J, Elouardighi H, Darrow AL, Andrade-Gordon P, Steinberg SF. 2003. Mechanisms of protease-activated receptor-4 actions in cardiomyocytes. Role of Src tyrosine kinase. J Biol Chem 278: 11714-11720.
Chay CH, Cooper CR, Gendernalik JD, Dhanasekaran SM, Chinnaiyan AM, Rubin MA, Schmaier AH, Pienta KJ. 2002. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 60: 760-765.
Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger S, Page G, Pavirani A, Lecocq JP, Pouyssegur J, Obberghen-Schilling JE. 1991. cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett 288: 123-128.
Even-Ram SC, Maoz M, Pokroy E, Reich R, Katz BZ, Gutwein P, Altevogt P, Bar-Shavit R. 2001. Tumor cell invasion is promoted by activation of protease-activated receptor-1 in cooperation with αvß5 integrin. J Biol Chem 276: 10952-10962.
Bradford MM. 1976. A refined and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. 2000. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 404: 609-613.
Henrikson KP, Salazar SL, Fenton JW, Pentecost BT. 1999. Role of thrombin receptor in breast cancer invasiveness. Br J Cancer 179: 401-406.
Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. 2003. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induce cell proliferation and motility in human colon cancer cells. Am J Pathol 162: 1503-1513.
Branda M, Wands JR. 2006. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 43: 891-902.
Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M. 2000. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1, 3-diamine hydrochloride (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 60: 1425-1434.
Nierodzik ML, Chen K, Takeshita K, Li JJ, Huang YQ, Feng XS, D'Andrea MR, Andrade-Gordon P, Karpatkin S. 1998. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 92: 3694-3700.
Cottrell GS, Amadesi S, Grady EF, Bunnett NW. 2004. Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. J Biol Chem 279: 13532-13539.
Bar-Shavit R, Mudd M, Wilner G, Mann K, Fenton JW, II. 1983. Monocyte chemotaxis: Stimulation by specific exosite region in thrombin. Science 220: 728-731.
Ossovskaya VS, Bunnett NW. 2004. Protease-activated receptors: Contribution to physiology and disease. Physiol Rev 84: 579-621.
Tellez C, Bar-Eli M. 2003. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 22: 3130-3137.
Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM. 2004. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2: 395-402.
Kaufmann R, Schafberg H, Rudroff C, Nowak G. 1997. Thrombin receptor activation results in calcium signalling and PKC-dependent Stimulation of DNA Synthesis in Hep-2 laryngeal carcinoma cells. Cancer 80: 2068-2074.
Roberts LR, Gores GJ. 2005. Hepatocellular carcinoma: Molecular pathways and new therapeutic targets. Sem Liv Dis 25: 212-225.
Zain J, Huang YQ, Feng X, Nierodzik ML, Li JJ, Karpatkin S. 2000. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 95: 3133-3138.
Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
Zacharski LR. 2003. Malignancy as a solid phase coagulopathy: Implications for the etiology, pathogenesis and treatment of cancer. Semin Thrombos Hemostas 29: 239-246.
Hollenberg MD, Saifeddine M. 2001. Proteinase-activated receptor 4 (PAR4): Activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Can J Physiol Pharmacol 79: 439-442.
Hangan D, Uniyal S, Morris VL, von Ballestrem C, Uniyal S, Chan BM. 1996. Integrin VLA-2 (α2ß1) function in postextravasation movement of human rhabdomyosarcoma RD cells in the liver. Cancer Res 56: 3142-3147.
Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. 1998. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 95: 6642-6646.
Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I, Bar-Shavit R. 1998. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4: 909-914.
Kaufmann R, Junker U, Nuske K, Westermann M, Henklein P, Scheele J, Junker K. 2002. PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells. Int J Oncol 20: 177-180.
Kawabata A, Saifeddine M, Al-Ani B, Leblond L, Hollenberg MD. 1999. Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: Activation of PAR2 by PAR1-targeted ligands. J Pharmacol Exp Ther 288: 358-370.
Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. 1999. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888.
Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, Wallace JL. 2005. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 102: 216-220.
Bergmann S, Junker K, Henklein P, Hollenberg MD, Settmacher U, Kaufmann R. 2006. PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration. Oncol Rep 15: 889-893.
Glenn K, Carney D, Fenton J, Cunningham D. 1980. Thrombin active-site regions required for fibroblast receptor binding and initiation of cell division. J Biol Chem 255: 6609-6616.
Galardy RE, Grobelny D, Foellmer HG, Fernandez LA. 1994. Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2-(hydroxamidocarbonymethyl)-4-methylpentanoyl)]-L-tryptophan methylamide. Cancer Res 54: 4715-4718.
Bromberg ME, Bailly MA, Konigsberg WH. 2001. Role of protease activated receptor 1 in tumor cell metastasis promoted by tissue factor. Thromb Haemost 86: 1210-1214.
Yin YJ, Salah Z, Maoz M, Ram SC, Ochayon S, Neufeld G, Katzav S, Bar-Shavit R. 2003. Oncogenic transformation induces tumor angiogenesis: A role for PAR1 activation. FASEB J 17: 163-174.
Vu TK, Hung DT, Wheaton VI, Coughlin SR. 1991. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057-1068.
D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P. 2001. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol 158: 2031-2041.
Hollenberg MD, Compton SJ. 2002. International Union of Pharmacology. XVIII. Proteinase-activated receptors. Pharmacol Rev 54: 203-217.
Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. 1997. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386: 502-506.
Wojtukiewicz MZ, Tang DG, Ben-Josef E, Renaud C, Walz DA, Honn KV. 1995. Solid tumor cells express functional "tethered ligand" thrombin receptor. Cancer Res 55: 698-704.
Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. 2005. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 3303-3313.
Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, Kuliopulos A. 2006. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113: 1244-1254.
1997; 80
2002; 54
2000; 95
2003; 17
2002; 60
2004; 2
1999; 288
2005; 26
2003; 278
1999; 402
1980; 255
2001; 86
1992; 52
2005; 25
2001; 61
1983; 220
2005; 102
1976; 72
2000; 404
1997; 386
2003; 162
2002; 104
2000; 60
1999; 179
1998; 92
1981
2006; 281
1998; 95
1996; 3
2004; 84
2000; 22
1995; 55
2006; 15
1996; 56
2006; 113
2001; 276
2004; 279
1991; 288
2005; 120
2002; 20
2006; 43
1991; 64
2003; 29
1994; 91
2001; 79
1998; 4
2005; 55
2001; 158
1994; 54
2003; 22
e_1_2_6_51_1
e_1_2_6_53_1
e_1_2_6_32_1
Kawabata A (e_1_2_6_28_1) 1999; 288
e_1_2_6_19_1
Galardy RE (e_1_2_6_17_1) 1994; 54
Glenn K (e_1_2_6_18_1) 1980; 255
e_1_2_6_13_1
e_1_2_6_36_1
e_1_2_6_11_1
e_1_2_6_34_1
e_1_2_6_15_1
e_1_2_6_38_1
e_1_2_6_43_1
e_1_2_6_20_1
Bromberg ME (e_1_2_6_9_1) 2001; 86
e_1_2_6_41_1
Lynn M (e_1_2_6_30_1) 1992; 52
e_1_2_6_7_1
e_1_2_6_24_1
e_1_2_6_49_1
e_1_2_6_3_1
e_1_2_6_22_1
e_1_2_6_45_1
e_1_2_6_26_1
e_1_2_6_47_1
e_1_2_6_52_1
Fischer EG (e_1_2_6_16_1) 1995; 55
e_1_2_6_10_1
Kamath L (e_1_2_6_25_1) 2001; 61
e_1_2_6_31_1
e_1_2_6_50_1
Bergmann S (e_1_2_6_4_1) 2006; 15
e_1_2_6_14_1
e_1_2_6_35_1
e_1_2_6_12_1
e_1_2_6_33_1
Kaufmann R (e_1_2_6_27_1) 2002; 20
Wojtukiewicz MZ (e_1_2_6_48_1) 1995; 55
e_1_2_6_39_1
e_1_2_6_37_1
e_1_2_6_42_1
e_1_2_6_21_1
e_1_2_6_40_1
e_1_2_6_8_1
e_1_2_6_6_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_29_1
e_1_2_6_44_1
Berndt M (e_1_2_6_5_1) 1981
e_1_2_6_46_1
References_xml – volume: 158
  start-page: 2031
  year: 2001
  end-page: 2041
  article-title: Differential expression of protease‐activated receptors‐1 and ‐2 in stromal fibroblasts of normal, benign, and malignant human tissues
  publication-title: Am J Pathol
– volume: 2
  start-page: 395
  year: 2004
  end-page: 402
  article-title: Protease‐activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis
  publication-title: Mol Cancer Res
– volume: 288
  start-page: 358
  year: 1999
  end-page: 370
  article-title: Evaluation of proteinase‐activated receptor‐1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: Activation of PAR2 by PAR1‐targeted ligands
  publication-title: J Pharmacol Exp Ther
– volume: 26
  start-page: 1
  year: 2005
  end-page: 43
  article-title: Proteinase‐activated receptors: Transducers of proteinase‐mediated signaling in inflammation and immune response
  publication-title: Endocr Rev
– volume: 56
  start-page: 3142
  year: 1996
  end-page: 3147
  article-title: Integrin VLA‐2 (α ß ) function in postextravasation movement of human rhabdomyosarcoma RD cells in the liver
  publication-title: Cancer Res
– volume: 55
  start-page: 74
  year: 2005
  end-page: 108
  article-title: Global cancer statistics, 2002
  publication-title: CA Cancer J Clin
– volume: 29
  start-page: 239
  year: 2003
  end-page: 246
  article-title: Malignancy as a solid phase coagulopathy: Implications for the etiology, pathogenesis and treatment of cancer
  publication-title: Semin Thrombos Hemostas
– volume: 281
  start-page: 32095
  year: 2006
  end-page: 32112
  article-title: Proteinase‐activated receptors, targets for Kallikrein signaling
  publication-title: J Biol Chem
– volume: 278
  start-page: 11714
  year: 2003
  end-page: 11720
  article-title: Mechanisms of protease‐activated receptor‐4 actions in cardiomyocytes. Role of Src tyrosine kinase
  publication-title: J Biol Chem
– volume: 86
  start-page: 1210
  year: 2001
  end-page: 1214
  article-title: Role of protease activated receptor 1 in tumor cell metastasis promoted by tissue factor
  publication-title: Thromb Haemost
– volume: 84
  start-page: 579
  year: 2004
  end-page: 621
  article-title: Protease‐activated receptors: Contribution to physiology and disease
  publication-title: Physiol Rev
– volume: 55
  start-page: 1629
  year: 1995
  end-page: 1632
  article-title: Tissue factor‐initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells
  publication-title: Cancer Res
– volume: 102
  start-page: 216
  year: 2005
  end-page: 220
  article-title: Proteinase‐activated receptors 1 and 4 counter‐regulate endostatin and VEGF release from human platelets
  publication-title: Proc Natl Acad Sci USA
– volume: 22
  start-page: 3130
  year: 2003
  end-page: 3137
  article-title: Role and regulation of the thrombin receptor (PAR‐1) in human melanoma
  publication-title: Oncogene
– volume: 60
  start-page: 1425
  year: 2000
  end-page: 1434
  article-title: Inhibition of cellular action of thrombin by N3‐cyclopropyl‐7‐[[4‐(1‐methylethyl)phenyl]methyl]‐7H‐pyrrolo[3, 2‐f]quinazoline‐1, 3‐diamine hydrochloride (SCH 79797), a nonpeptide thrombin receptor antagonist
  publication-title: Biochem Pharmacol
– volume: 54
  start-page: 203
  year: 2002
  end-page: 217
  article-title: International Union of Pharmacology. XVIII. Proteinase‐activated receptors
  publication-title: Pharmacol Rev
– volume: 220
  start-page: 728
  year: 1983
  end-page: 731
  article-title: Monocyte chemotaxis: Stimulation by specific exosite region in thrombin
  publication-title: Science
– volume: 79
  start-page: 439
  year: 2001
  end-page: 442
  article-title: Proteinase‐activated receptor 4 (PAR4): Activation and inhibition of rat platelet aggregation by PAR4‐derived peptides
  publication-title: Can J Physiol Pharmacol
– volume: 120
  start-page: 3303
  year: 2005
  end-page: 3313
  article-title: PAR1 is a matrix metalloprotease‐1 receptor that promotes invasion and tumorigenesis of breast cancer cells
  publication-title: Cell
– volume: 404
  start-page: 609
  year: 2000
  end-page: 613
  article-title: PAR3 is a cofactor for PAR4 activation by thrombin
  publication-title: Nature
– volume: 17
  start-page: 163
  year: 2003
  end-page: 174
  article-title: Oncogenic transformation induces tumor angiogenesis: A role for PAR1 activation
  publication-title: FASEB J
– volume: 54
  start-page: 4715
  year: 1994
  end-page: 4718
  article-title: Inhibition of angiogenesis by the matrix metalloprotease inhibitor N‐[2R‐2‐(hydroxamidocarbonymethyl)‐4‐methylpentanoyl)]‐L‐tryptophan methylamide
  publication-title: Cancer Res
– volume: 402
  start-page: 884
  year: 1999
  end-page: 888
  article-title: EGF receptor transactivation by G‐protein‐coupled receptors requires metalloproteinase cleavage of proHB‐EGF
  publication-title: Nature
– volume: 55
  start-page: 698
  year: 1995
  end-page: 704
  article-title: Solid tumor cells express functional “tethered ligand” thrombin receptor
  publication-title: Cancer Res
– volume: 20
  start-page: 177
  year: 2002
  end-page: 180
  article-title: PAR‐1‐ and PAR‐3‐type thrombin receptor expression in primary cultures of human renal cell carcinoma cells
  publication-title: Int J Oncol
– volume: 52
  start-page: 3267
  year: 1992
  end-page: 3272
  article-title: Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo
  publication-title: Cancer Res
– volume: 15
  start-page: 889
  year: 2006
  end-page: 893
  article-title: PAR‐type thrombin receptors in renal carcinoma cells: PAR ‐mediated EGFR activation promotes cell migration
  publication-title: Oncol Rep
– volume: 61
  start-page: 5933
  year: 2001
  end-page: 5940
  article-title: Signaling form protease‐activated receptor‐1 inhibits migration and invasion of breast cancer cells
  publication-title: Cancer Res
– volume: 113
  start-page: 1244
  year: 2006
  end-page: 1254
  article-title: Blocking the protease‐activated receptor 1‐4 heterodimer in platelet‐mediated thrombosis
  publication-title: Circulation
– volume: 179
  start-page: 401
  year: 1999
  end-page: 406
  article-title: Role of thrombin receptor in breast cancer invasiveness
  publication-title: Br J Cancer
– volume: 92
  start-page: 3694
  year: 1998
  end-page: 3700
  article-title: Protease‐activated receptor 1 (PAR‐1) is required and rate‐limiting for thrombin‐enhanced experimental pulmonary metastasis
  publication-title: Blood
– volume: 276
  start-page: 10952
  year: 2001
  end-page: 10962
  article-title: Tumor cell invasion is promoted by activation of protease‐activated receptor‐1 in cooperation with α ß integrin
  publication-title: J Biol Chem
– volume: 255
  start-page: 6609
  year: 1980
  end-page: 6616
  article-title: Thrombin active‐site regions required for fibroblast receptor binding and initiation of cell division
  publication-title: J Biol Chem
– volume: 2
  start-page: 777
  year: 2004
  end-page: 784
  article-title: Rationale for clinical trials of coagulation: Reactive drugs in hepatocellular carcinoma
  publication-title: Expert Rev Cardiovasc Ther
– volume: 80
  start-page: 2068
  year: 1997
  end-page: 2074
  article-title: Thrombin receptor activation results in calcium signalling and PKC‐dependent Stimulation of DNA Synthesis in Hep‐2 laryngeal carcinoma cells
  publication-title: Cancer
– volume: 43
  start-page: 891
  year: 2006
  end-page: 902
  article-title: Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma
  publication-title: Hepatology
– volume: 162
  start-page: 1503
  year: 2003
  end-page: 1513
  article-title: Aberrant expression and activation of the thrombin receptor protease‐activated receptor‐1 induce cell proliferation and motility in human colon cancer cells
  publication-title: Am J Pathol
– volume: 104
  start-page: 2746
  year: 2002
  end-page: 2751
  article-title: Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis
  publication-title: Blood
– volume: 25
  start-page: 212
  year: 2005
  end-page: 225
  article-title: Hepatocellular carcinoma: Molecular pathways and new therapeutic targets
  publication-title: Sem Liv Dis
– volume: 95
  start-page: 3133
  year: 2000
  end-page: 3138
  article-title: Concentration‐dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells
  publication-title: Blood
– volume: 64
  start-page: 1057
  year: 1991
  end-page: 1068
  article-title: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
  publication-title: Cell
– volume: 60
  start-page: 760
  year: 2002
  end-page: 765
  article-title: A functional thrombin receptor (PAR1) is expressed on bone‐derived prostate cancer cell lines
  publication-title: Urology
– start-page: 43
  year: 1981
  end-page: 47
– volume: 279
  start-page: 13532
  year: 2004
  end-page: 13539
  article-title: Trypsin IV, a novel agonist of protease‐activated receptors 2 and 4
  publication-title: J Biol Chem
– volume: 72
  start-page: 248
  year: 1976
  end-page: 254
  article-title: A refined and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein‐dye binding
  publication-title: Anal Biochem
– volume: 288
  start-page: 123
  year: 1991
  end-page: 128
  article-title: cDNA cloning and expression of a hamster alpha‐thrombin receptor coupled to Ca mobilization
  publication-title: FEBS Lett
– volume: 386
  start-page: 502
  year: 1997
  end-page: 506
  article-title: Protease‐activated receptor 3 is a second thrombin receptor in humans
  publication-title: Nature
– volume: 4
  start-page: 909
  year: 1998
  end-page: 914
  article-title: Thrombin receptor overexpression in malignant and physiological invasion processes
  publication-title: Nat Med
– volume: 95
  start-page: 6642
  year: 1998
  end-page: 6646
  article-title: Cloning and characterization of human protease‐activated receptor 4
  publication-title: Proc Natl Acad Sci USA
– volume: 22
  start-page: 281
  year: 2000
  end-page: 287
  article-title: Hemostatic factors in tumor biology
  publication-title: J Pediatr Hematol Oncol
– volume: 91
  start-page: 9208
  year: 1994
  end-page: 9212
  article-title: Molecular cloning of a potential proteinase activated receptor
  publication-title: Proc Natl Acad Sci USA
– volume: 3
  start-page: 379
  year: 1996
  end-page: 384
  article-title: Tissue factor in cancer angiogenesis and metastasis
  publication-title: Curr Opin Hematol
– ident: e_1_2_6_53_1
  doi: 10.1182/blood.V95.10.3133
– ident: e_1_2_6_29_1
  doi: 10.1161/CIRCULATIONAHA.105.587758
– ident: e_1_2_6_47_1
  doi: 10.1016/0092-8674(91)90261-V
– ident: e_1_2_6_36_1
  doi: 10.1152/physrev.00028.2003
– start-page: 43
  volume-title: Platelets in biology and pathology
  year: 1981
  ident: e_1_2_6_5_1
  contributor:
    fullname: Berndt M
– ident: e_1_2_6_39_1
  doi: 10.1038/47260
– volume: 20
  start-page: 177
  year: 2002
  ident: e_1_2_6_27_1
  article-title: PAR‐1‐ and PAR‐3‐type thrombin receptor expression in primary cultures of human renal cell carcinoma cells
  publication-title: Int J Oncol
  contributor:
    fullname: Kaufmann R
– ident: e_1_2_6_14_1
  doi: 10.1038/nm0898-909
– ident: e_1_2_6_26_1
  doi: 10.1002/(SICI)1097-0142(19971201)80:11<2068::AID-CNCR5>3.0.CO;2-T
– ident: e_1_2_6_35_1
  doi: 10.1074/jbc.M513138200
– ident: e_1_2_6_52_1
  doi: 10.1586/14779072.2.5.777
– ident: e_1_2_6_7_1
  doi: 10.1016/0003-2697(76)90527-3
– ident: e_1_2_6_32_1
  doi: 10.1038/35007085
– ident: e_1_2_6_50_1
  doi: 10.1096/fj.02-0316com
– ident: e_1_2_6_11_1
  doi: 10.1074/jbc.M312090200
– ident: e_1_2_6_22_1
  doi: 10.1139/y01-013
– ident: e_1_2_6_24_1
  doi: 10.1038/386502a0
– ident: e_1_2_6_51_1
  doi: 10.1055/s-2003-40962
– volume: 55
  start-page: 1629
  year: 1995
  ident: e_1_2_6_16_1
  article-title: Tissue factor‐initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells
  publication-title: Cancer Res
  contributor:
    fullname: Fischer EG
– ident: e_1_2_6_40_1
  doi: 10.1016/0014-5793(91)81017-3
– ident: e_1_2_6_21_1
  doi: 10.1124/pr.54.2.203
– ident: e_1_2_6_43_1
  doi: 10.1074/jbc.M213091200
– ident: e_1_2_6_31_1
  doi: 10.1073/pnas.0406682102
– volume: 55
  start-page: 698
  year: 1995
  ident: e_1_2_6_48_1
  article-title: Solid tumor cells express functional “tethered ligand” thrombin receptor
  publication-title: Cancer Res
  contributor:
    fullname: Wojtukiewicz MZ
– volume: 54
  start-page: 4715
  year: 1994
  ident: e_1_2_6_17_1
  article-title: Inhibition of angiogenesis by the matrix metalloprotease inhibitor N‐[2R‐2‐(hydroxamidocarbonymethyl)‐4‐methylpentanoyl)]‐L‐tryptophan methylamide
  publication-title: Cancer Res
  contributor:
    fullname: Galardy RE
– ident: e_1_2_6_33_1
  doi: 10.1182/blood.V92.10.3694
– ident: e_1_2_6_3_1
  doi: 10.1126/science.6836310
– ident: e_1_2_6_6_1
  doi: 10.1016/j.cell.2004.12.018
– ident: e_1_2_6_45_1
  doi: 10.1210/er.2003-0025
– ident: e_1_2_6_10_1
  doi: 10.1016/S0090-4295(02)01969-6
– ident: e_1_2_6_38_1
  doi: 10.3322/canjclin.55.2.74
– volume: 15
  start-page: 889
  year: 2006
  ident: e_1_2_6_4_1
  article-title: PAR‐type thrombin receptors in renal carcinoma cells: PAR1‐mediated EGFR activation promotes cell migration
  publication-title: Oncol Rep
  contributor:
    fullname: Bergmann S
– ident: e_1_2_6_37_1
  doi: 10.1097/00043426-200005000-00019
– ident: e_1_2_6_12_1
  doi: 10.1016/S0002-9440(10)64675-5
– ident: e_1_2_6_49_1
  doi: 10.1073/pnas.95.12.6642
– ident: e_1_2_6_41_1
  doi: 10.1055/s-2005-871200
– ident: e_1_2_6_8_1
  doi: 10.1002/hep.21196
– ident: e_1_2_6_15_1
  doi: 10.1074/jbc.M007027200
– volume: 288
  start-page: 358
  year: 1999
  ident: e_1_2_6_28_1
  article-title: Evaluation of proteinase‐activated receptor‐1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: Activation of PAR2 by PAR1‐targeted ligands
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Kawabata A
– ident: e_1_2_6_34_1
  doi: 10.1073/pnas.91.20.9208
– volume: 255
  start-page: 6609
  year: 1980
  ident: e_1_2_6_18_1
  article-title: Thrombin active‐site regions required for fibroblast receptor binding and initiation of cell division
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)43613-7
  contributor:
    fullname: Glenn K
– ident: e_1_2_6_44_1
  doi: 10.1158/1541-7786.395.2.7
– ident: e_1_2_6_19_1
  doi: 10.1007/BF00132981
– ident: e_1_2_6_42_1
  doi: 10.1097/00062752-199603050-00008
– volume: 86
  start-page: 1210
  year: 2001
  ident: e_1_2_6_9_1
  article-title: Role of protease activated receptor 1 in tumor cell metastasis promoted by tissue factor
  publication-title: Thromb Haemost
  doi: 10.1055/s-0037-1616053
  contributor:
    fullname: Bromberg ME
– ident: e_1_2_6_46_1
  doi: 10.1038/sj.onc.1206453
– ident: e_1_2_6_13_1
  doi: 10.1016/S0002-9440(10)64283-6
– ident: e_1_2_6_20_1
  doi: 10.1038/sj.bjc.6690063
– volume: 52
  start-page: 3267
  year: 1992
  ident: e_1_2_6_30_1
  article-title: Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo
  publication-title: Cancer Res
  contributor:
    fullname: Lynn M
– volume: 61
  start-page: 5933
  year: 2001
  ident: e_1_2_6_25_1
  article-title: Signaling form protease‐activated receptor‐1 inhibits migration and invasion of breast cancer cells
  publication-title: Cancer Res
  contributor:
    fullname: Kamath L
– ident: e_1_2_6_23_1
  doi: 10.1182/blood-2004-03-1047
– ident: e_1_2_6_2_1
  doi: 10.1016/S0006-2952(00)00460-3
SSID ssj0009933
Score 2.1513476
Snippet Proteinase‐activated receptor‐1 (PAR1), a thrombin receptor and the prototype of a newly discovered G‐protein‐coupled receptor subfamily, plays an important...
Proteinase-activated receptor-1 (PAR(1)), a thrombin receptor and the prototype of a newly discovered G-protein-coupled receptor subfamily, plays an important...
Abstract Proteinase‐activated receptor‐1 (PAR 1 ), a thrombin receptor and the prototype of a newly discovered G‐protein‐coupled receptor subfamily, plays an...
SourceID proquest
crossref
pubmed
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 699
SubjectTerms Calcium - metabolism
Carcinoma, Hepatocellular - metabolism
Carcinoma, Hepatocellular - pathology
Cell Line, Tumor
Cell Movement - drug effects
Cell Movement - physiology
Cyclic AMP-Dependent Protein Kinases - antagonists & inhibitors
Cyclic AMP-Dependent Protein Kinases - metabolism
Enzyme Inhibitors - pharmacology
GTP-Binding Protein alpha Subunits, Gi-Go - metabolism
Hemostatics - pharmacology
Humans
Liver Neoplasms - metabolism
Liver Neoplasms - pathology
MAP Kinase Signaling System - drug effects
MAP Kinase Signaling System - physiology
Matrix Metalloproteinases - metabolism
Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors
Mitogen-Activated Protein Kinase 1 - metabolism
Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors
Mitogen-Activated Protein Kinase 3 - metabolism
Phosphorylation
Protein Kinase C - antagonists & inhibitors
Protein Kinase C - metabolism
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - metabolism
Receptor, PAR-1 - genetics
Receptor, PAR-1 - metabolism
Receptors, Thrombin - genetics
Receptors, Thrombin - metabolism
Signal Transduction - drug effects
Signal Transduction - physiology
src-Family Kinases - antagonists & inhibitors
src-Family Kinases - metabolism
Thrombin - pharmacology
Title Thrombin-mediated hepatocellular carcinoma cell migration: Cooperative action via proteinase-activated receptors 1 and 4
URI https://api.istex.fr/ark:/67375/WNG-G6SX5Z45-3/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.21027
https://www.ncbi.nlm.nih.gov/pubmed/17323377
https://search.proquest.com/docview/70331382
Volume 211
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1faxQxEB9KpeCLra3as2qDSPFlr7ubZHOrT-X6j4JFtMVDhJBNsu1Zbve43hVb-uBH8DP6SZwkt3dUFMS3Jewm2WQy80sy8xuAV1kqUm6ojgprVMSEQD1IYxNZzkRJmS6Vz9bw7jg7PGVHPd5bgLdNLEzgh5gduLmV4fW1W-CquNyek4Z-1cO226-4SPKECufOtfthTh2VT9PIexcEzpKGVShOt2df3rFF99ywfvsT0LyLW73h2V-GL02Xg7_JRXsyLtr65jc2x__8pxV4MAWkZCdI0ENYsNUqrO1UuBkfXJMt4l1E_dn7KiyFzJXXa3B7cj6qB7ir_vn9hw8-QeBKztG0jWt3FeB8W4l2aYqqeqCIKyKD_lmQtjekW9dDGyjHSQisIFd9RTxnRL9Cu4q1uvIrXy3qZDt0SYFIQlRlCHsEp_t7J93DaJrIIdLMXRGbWGkUBcpzjQiTCoM4pFB5mSZGl7HmqmNLpgvB80znhUNsRiGS1B1BqRHK0MewWNWVXQfSQfGJS0Wzjs6ZKm1hVIoaGicYpQ6LWvCymVI5DHwdMjAzpxJHV_rRbcGWn-zZG2p04RzcBJefjg_kQfaxxz8zLmkLNhtpkLjs3GipytaTS4mKkjr6xhY8CUIyb03QlFKBjbz2U_33bsij7nv_8PTfX92A-43HYpw8g8XxaGKfIywaFy-8_P8CgesL8Q
link.rule.ids 315,783,787,1378,27936,27937,46306,46730
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD4amxC8cNm4lNsshCZe0qWxHTeIl6mwlbFVCDqtQkKWYzusTE2q0k4M8cBP4DfySzi2m1ZDICHeIiuxneNzjj_bx98BeJImIuGG6ii3RkVMCPSDNDaR5UwUlOlC-WwNh720e8T2B3ywAs_ruzCBH2Kx4eYsw_trZ-BuQ3p7yRr6SY-bbsEiLsEamjt1iRtevF2SR2XzRPI-CIGzVs0rFCfbi08vzEZrTrBf_gQ1LyJXP_XsXocPdadDxMlpczbNm_rrb3yO__tXN-DaHJOSnaBEN2HFluuwsVPienx0TraIjxL12-_rcDkkrzzfgG_9k0k1woX1z-8__P0TxK7kBGe3aeVOA1x4K9EuU1FZjRRxRWQ0_BgU7hnpVNXYBtZxEu5WkLOhIp42Ylji1Iq1uvIzXy26ZTt2eYFIi6jSEHYLjnZf9jvdaJ7LIdLMnRKbWGnUBsozjSCTCoNQJFdZkbSMLmLNVdsWTOeCZ6nOcgfajEIwqduCUiOUobdhtaxKexdIGzUoLhRN2zpjqrC5UQk6aRxhVDwsasDjekzlOFB2yEDOnEiUrvTSbcCWH-3FG2py6mLcBJfHvT25l74b8PeMS9qAzVodJFqek5YqbTX7LNFXUsfg2IA7QUuWrQmaUCqwkad-rP_eDbnfeeMf7v37q5twpds_PJAHr3qv78PVOoAxbj2A1elkZh8iSprmj7wx_AIZVRAJ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD4am0C8cNm4lNsshCZe0qWxHTfwNBW6MaCaYBMVQrIc22FlahKVdmKIB34Cv5FfwrHdtBoCCfEWWYntHJ9z_Nk-_g7AozQRCTdUR7k1KmJCoB-ksYksZ6KgTBfKZ2t4PUj3jtj-kA9X4GlzFybwQyw23JxleH_tDLw2xfaSNPSTrttuvSIuwBpLEfk6RPRmyR2VzfPI-xgEzjoNrVCcbC8-PTcZrTm5fvkT0jwPXP3M078KH5o-h4CTk_Zsmrf119_oHP_zp67BlTkiJTtBha7Dii3XYWOnxNX4-IxsER8j6jff1-FiSF15tgHfDo8n1RiX1T-___C3TxC5kmOc26aVOwtwwa1EuzxFZTVWxBWR8ehjULcnpFdVtQ2c4yTcrCCnI0U8acSoxIkVa3Xlp75adMq2dlmBSIeo0hB2A476zw97e9E8k0OkmTsjNrHSqAuUZxohJhUGgUiusiLpGF3EmquuLZjOBc9SneUOshmFUFJ3BaVGKENvwmpZlfY2kC7qT1womnZ1xlRhc6MSdNE4wKh2WNSCh82QyjoQdshAzZxIlK700m3Blh_sxRtqcuIi3ASX7wa7cjd9O-TvGZe0BZuNNki0OyctVdpq9lmip6SOv7EFt4KSLFsTNKFUYCOP_VD_vRtyv3fgH-78-6ubcOngWV--ejF4eRcuN9GLcecerE4nM3sfIdI0f-BN4RfsbA64
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thrombin%E2%80%90mediated+hepatocellular+carcinoma+cell+migration%3A+Cooperative+action+via+proteinase%E2%80%90activated+receptors+1+and+4&rft.jtitle=Journal+of+cellular+physiology&rft.au=Kaufmann%2C+Roland&rft.au=Rahn%2C+Stephanie&rft.au=Pollrich%2C+Kristin&rft.au=Hertel%2C+Julia&rft.date=2007-06-01&rft.issn=0021-9541&rft.eissn=1097-4652&rft.volume=211&rft.issue=3&rft.spage=699&rft.epage=707&rft_id=info:doi/10.1002%2Fjcp.21027&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_jcp_21027
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon